Hit and lead profiling : identification and optimization of drug-like molecules
著者
書誌事項
Hit and lead profiling : identification and optimization of drug-like molecules
（Methods and principles in medicinal chemistry / edited by R. Mannhold ... [et al.], v. 43）
Wiley-VCH, c2009
- タイトル別名
-
Identification and optimization of drug-like molecules
大学図書館所蔵 件 / 全1件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
HTTP:URL=http://www.loc.gov/catdir/enhancements/fy1007/2010286582-b.html Information=Contributor biographical information
HTTP:URL=http://www.loc.gov/catdir/enhancements/fy1007/2010286582-d.html Information=Publisher description
HTTP:URL=http://www.loc.gov/catdir/enhancements/fy1007/2010286582-t.html Information=Table of contents only
内容説明・目次
内容説明
The only reference on current methods to generate pharmacokinetic and safety profiles of drug candidates, as well as how they must be balanced against one other for the best selection of candidates for further development.
Following a brief introduction to the necessities of filtering and risk assessment of potential new drug molecules before actual drug development, the two equally important aspects of pharmacological (ADME) and safety (toxicity) profiling are covered in separate parts.
The ADME section covers the profiling of basic physicochemical parameters, such as solubility and permeability, as well as more complex traits, such as the likelihood of drug-drug interactions, metabolic clearance and protein binding properties.
The toxicology part addresses, among others, recent advances in early genetic toxicity testing, bioactivation screening, organ-specific toxicity assays for liver, heart, kidney and blood, as well as profiling for autoimmune reactions.
By addressing both drug efficiency and drug safety, this modern practical reference shows readers how each individual aspect figures in shaping the key decisions on which the entire drug development process hinges. In short, this is a complete toolbox for assessing the risk/benefit ratio for any novel compound during the early drug development stages, using both in vitro and in silico methods.
Both editors are based at one of the leading research-driven pharmaceutical companies, and the authors have been recruited from numerous other global players in the field.
Invaluable know-how for every medicinal chemist and drug developer.
目次
PART 1: Introduction: The one Airplane that Flies -
Selection of the Right one Molecule for Clinical use.
1 Process logistics, testing strategies and automation aspects
2 Prediction of drug-likeness and its integration
3 Integrative risk assessment
PART 2: ADME Profiling: What is Drug Likeness?
4 Solubility and Aggregation
5 In silico tools and in vitro HTS approaches to determine lipophilicity during the drug discovery process
6 Membrane permeability - measurement and prediction in drug discovery
7 Drug Metabolism and Reactive Metabolites
8 Drug-Drug Interactions: Screening for liability and assessment of risk
9 Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery
10 Putting it all together
PART 3: Safety Profiling: What is Considered Safe in the Clinic?
11 Genetic Toxicity: in vitro Approaches for Hit and Lead Profiling
12 In vitro Safety Pharmacology Profiling: An important tool to decrease attrition
13 Knowledge-based and Computational Approaches to in vitro Safety Pharmacology
PART 4: Organ Specific Toxicity
14 Discovery Toxicology Screening: Predictive, In Vitro Cytotoxicity
15 Predicting Drug-Induced Hepatotoxicity: In Vitro, In Silico, and In Vivo Approaches
16 Should cardiosafety be ruled by hERG inhibition? Early testing scenarios and integrated risk assessment
17 Haematotoxicity: in vitro and ex vivo compound profiling
18 Profiling Adverse Immune Effects
19 In Vitro Phototoxicity Testing: A Procedure Involving Multiple Endpoints
「Nielsen BookData」 より
